11.62 USD
+0.08 (+0.69%)
Taking everything into account, VREX scores 5 out of 10 in our fundamental rating. VREX was compared to 188 industry peers in the Health Care Equipment & Supplies industry. VREX has only an average score on both its financial health and profitability. VREX has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
VREX had positive earnings in the past year.
VREX had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: VREX reported negative net income in multiple years.
In the past 5 years VREX always reported a positive cash flow from operatings.
1.2 Ratios
VREX's Return On Assets of -6.35% is fine compared to the rest of the industry. VREX outperforms 64.89% of its industry peers.
The Return On Equity of VREX (-14.88%) is better than 63.30% of its industry peers.
VREX has a Return On Invested Capital of 5.67%. This is in the better half of the industry: VREX outperforms 78.72% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for VREX is below the industry average of 8.78%.
The 3 year average ROIC (4.82%) for VREX is below the current ROIC(5.67%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6.35% | ||
| ROE | -14.88% | ||
| ROIC | 5.67% |
ROA(3y)-2.14%
ROA(5y)-0.47%
ROE(3y)-5.1%
ROE(5y)-1.2%
ROIC(3y)4.82%
ROIC(5y)5.54%
1.3 Margins
Looking at the Operating Margin, with a value of 7.83%, VREX is in the better half of the industry, outperforming 74.47% of the companies in the same industry.
In the last couple of years the Operating Margin of VREX has declined.
Looking at the Gross Margin, with a value of 34.40%, VREX is doing worse than 73.94% of the companies in the same industry.
VREX's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 7.83% | ||
| PM (TTM) | N/A | ||
| GM | 34.4% |
OM growth 3Y-8.19%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.84%
GM growth 5Y5.76%
2. Health
2.1 Basic Checks
VREX has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for VREX has been increased compared to 1 year ago.
Compared to 5 years ago, VREX has more shares outstanding
The debt/assets ratio for VREX has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 1.90 indicates that VREX is not a great score, but indicates only limited risk for bankruptcy at the moment.
VREX has a Altman-Z score of 1.90. This is comparable to the rest of the industry: VREX outperforms 59.57% of its industry peers.
The Debt to FCF ratio of VREX is 19.87, which is on the high side as it means it would take VREX, 19.87 years of fcf income to pay off all of its debts.
VREX's Debt to FCF ratio of 19.87 is fine compared to the rest of the industry. VREX outperforms 70.21% of its industry peers.
VREX has a Debt/Equity ratio of 0.79. This is a neutral value indicating VREX is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.79, VREX is doing worse than 70.74% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.79 | ||
| Debt/FCF | 19.87 | ||
| Altman-Z | 1.9 |
ROIC/WACC0.76
WACC7.46%
2.3 Liquidity
A Current Ratio of 3.43 indicates that VREX has no problem at all paying its short term obligations.
With a decent Current ratio value of 3.43, VREX is doing good in the industry, outperforming 62.77% of the companies in the same industry.
VREX has a Quick Ratio of 1.83. This is a normal value and indicates that VREX is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.83, VREX perfoms like the industry average, outperforming 46.81% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.43 | ||
| Quick Ratio | 1.83 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 60.00% over the past year.
The Earnings Per Share has been growing by 57.78% on average over the past years. This is a very strong growth
Looking at the last year, VREX shows a small growth in Revenue. The Revenue has grown by 4.14% in the last year.
Measured over the past years, VREX shows a small growth in Revenue. The Revenue has been growing by 2.73% on average per year.
EPS 1Y (TTM)60%
EPS 3Y-14.54%
EPS 5Y57.78%
EPS Q2Q%94.74%
Revenue 1Y (TTM)4.14%
Revenue growth 3Y-0.58%
Revenue growth 5Y2.73%
Sales Q2Q%11.28%
3.2 Future
VREX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.20% yearly.
Based on estimates for the next years, VREX will show a small growth in Revenue. The Revenue will grow by 3.86% on average per year.
EPS Next Y-6.84%
EPS Next 2Y8.2%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year2.97%
Revenue Next 2Y3.86%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 13.20, VREX is valued correctly.
Based on the Price/Earnings ratio, VREX is valued cheaply inside the industry as 89.89% of the companies are valued more expensively.
Compared to an average S&P500 Price/Earnings ratio of 26.41, VREX is valued a bit cheaper.
A Price/Forward Earnings ratio of 14.17 indicates a correct valuation of VREX.
Based on the Price/Forward Earnings ratio, VREX is valued cheaply inside the industry as 88.83% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of VREX to the average of the S&P500 Index (35.40), we can say VREX is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.2 | ||
| Fwd PE | 14.17 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, VREX is valued cheaply inside the industry as 95.74% of the companies are valued more expensively.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of VREX indicates a rather cheap valuation: VREX is cheaper than 82.98% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 25.77 | ||
| EV/EBITDA | 7.39 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)0.23
EPS Next 2Y8.2%
EPS Next 3YN/A
5. Dividend
5.1 Amount
VREX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:VREX (12/5/2025, 2:01:52 PM)
11.62
+0.08 (+0.69%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners95.29%
Inst Owner Change2.62%
Ins Owners1.66%
Ins Owner Change-1.28%
Market Cap484.55M
Revenue(TTM)844.60M
Net Income(TTM)-70.30M
Analysts83.64
Price Target18.16 (56.28%)
Short Float %2.04%
Short Ratio2.85
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)251.48%
Min EPS beat(2)98.76%
Max EPS beat(2)404.2%
EPS beat(4)4
Avg EPS beat(4)167.83%
Min EPS beat(4)81.21%
Max EPS beat(4)404.2%
EPS beat(8)5
Avg EPS beat(8)85.78%
EPS beat(12)9
Avg EPS beat(12)64.21%
EPS beat(16)12
Avg EPS beat(16)54.96%
Revenue beat(2)2
Avg Revenue beat(2)3.46%
Min Revenue beat(2)2.35%
Max Revenue beat(2)4.57%
Revenue beat(4)3
Avg Revenue beat(4)1.33%
Min Revenue beat(4)-3.1%
Max Revenue beat(4)4.57%
Revenue beat(8)4
Avg Revenue beat(8)0.25%
Revenue beat(12)5
Avg Revenue beat(12)-0.02%
Revenue beat(16)8
Avg Revenue beat(16)-0.05%
PT rev (1m)2.3%
PT rev (3m)2.3%
EPS NQ rev (1m)-2.44%
EPS NQ rev (3m)-8.05%
EPS NY rev (1m)0%
EPS NY rev (3m)1.42%
Revenue NQ rev (1m)0.72%
Revenue NQ rev (3m)0.58%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 13.2 | ||
| Fwd PE | 14.17 | ||
| P/S | 0.57 | ||
| P/FCF | 25.77 | ||
| P/OCF | 11.62 | ||
| P/B | 1.03 | ||
| P/tB | 1.86 | ||
| EV/EBITDA | 7.39 |
EPS(TTM)0.88
EY7.57%
EPS(NY)0.82
Fwd EY7.06%
FCF(TTM)0.45
FCFY3.88%
OCF(TTM)1
OCFY8.61%
SpS20.25
BVpS11.33
TBVpS6.24
PEG (NY)N/A
PEG (5Y)0.23
Graham Number14.98
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6.35% | ||
| ROE | -14.88% | ||
| ROCE | 7.18% | ||
| ROIC | 5.67% | ||
| ROICexc | 6.83% | ||
| ROICexgc | 9.45% | ||
| OM | 7.83% | ||
| PM (TTM) | N/A | ||
| GM | 34.4% | ||
| FCFM | 2.23% |
ROA(3y)-2.14%
ROA(5y)-0.47%
ROE(3y)-5.1%
ROE(5y)-1.2%
ROIC(3y)4.82%
ROIC(5y)5.54%
ROICexc(3y)5.86%
ROICexc(5y)6.54%
ROICexgc(3y)8.71%
ROICexgc(5y)10.09%
ROCE(3y)6.1%
ROCE(5y)7.01%
ROICexgc growth 3Y-6.75%
ROICexgc growth 5YN/A
ROICexc growth 3Y-3.38%
ROICexc growth 5YN/A
OM growth 3Y-8.19%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.84%
GM growth 5Y5.76%
F-Score5
Asset Turnover0.76
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.79 | ||
| Debt/FCF | 19.87 | ||
| Debt/EBITDA | 3.98 | ||
| Cap/Depr | 84.19% | ||
| Cap/Sales | 2.71% | ||
| Interest Coverage | 2.11 | ||
| Cash Conversion | 44.69% | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.43 | ||
| Quick Ratio | 1.83 | ||
| Altman-Z | 1.9 |
F-Score5
WACC7.46%
ROIC/WACC0.76
Cap/Depr(3y)77.68%
Cap/Depr(5y)67.38%
Cap/Sales(3y)2.78%
Cap/Sales(5y)2.53%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)60%
EPS 3Y-14.54%
EPS 5Y57.78%
EPS Q2Q%94.74%
EPS Next Y-6.84%
EPS Next 2Y8.2%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)4.14%
Revenue growth 3Y-0.58%
Revenue growth 5Y2.73%
Sales Q2Q%11.28%
Revenue Next Year2.97%
Revenue Next 2Y3.86%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y105.28%
EBIT growth 3Y-8.72%
EBIT growth 5YN/A
EBIT Next Year53.77%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-7.84%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-11.84%
OCF growth 3Y35.13%
OCF growth 5Y25.87%
VAREX IMAGING CORP / VREX FAQ
What is the fundamental rating for VREX stock?
ChartMill assigns a fundamental rating of 5 / 10 to VREX.
Can you provide the valuation status for VAREX IMAGING CORP?
ChartMill assigns a valuation rating of 6 / 10 to VAREX IMAGING CORP (VREX). This can be considered as Fairly Valued.
What is the profitability of VREX stock?
VAREX IMAGING CORP (VREX) has a profitability rating of 5 / 10.
Can you provide the financial health for VREX stock?
The financial health rating of VAREX IMAGING CORP (VREX) is 4 / 10.
What is the earnings growth outlook for VAREX IMAGING CORP?
The Earnings per Share (EPS) of VAREX IMAGING CORP (VREX) is expected to decline by -6.84% in the next year.